clinica < clinical < clinically

Facettes : Author.f AffPays.f AffRegion.f AffVille.f AffOrg.f KwdFr.f Mesh.f MeshFr.f Teeft.f

List of bibliographic references indexed by clinical

Number of relevant bibliographic references: 1741.
[0-20] [0 - 20][0 - 50][20-40]

Ident.	Authors (with country if any)	Title
000001 (2020)	A. Prasse [Allemagne] ; F. Bonella [Allemagne] ; U. Müller-Ladner [Allemagne] ; T. Witte [Allemagne] ; N. Hunzelmann [Allemagne] ; J. Distler [Allemagne]	[Treatment of systemic sclerosis-associated interstitial lung disease].
000003 (2020)	Charlotte Girard-Guyonvarc'H ; Michele Iudici	[Targeted therapies for connective tissue diseases and vasculitis].
000007 (2020)	Danièle Allali ; Marc Blondon ; Pascale Roux-Lombard ; David Spoerl	[How to manage giant cell arteritis].
000009 (2020)	C B Wu [République populaire de Chine] ; H Y Zhang [République populaire de Chine] ; S H Shao [République populaire de Chine] ; L W Dou [République populaire de Chine] ; Q Y Zhou [République populaire de Chine] ; Y. Liu [République populaire de Chine] ; W B Gao [République populaire de Chine] ; J H Zhu [République populaire de Chine]	[A report of six TAFRO syndrome: clinical characteristics, diagnosis and treatment analysis].
000010 (2020)	Aline Pfefferle [Australie] ; Nicholas D. Huntington [Australie]	You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy
000011 (2020)	Binqing Fu ; Xiaoling Xu ; Haiming Wei	Why tocilizumab could be an effective treatment for severe COVID-19?
000012 (2020)	Seoyoung C. Kim [États-Unis] ; Sebastian Schneeweiss [États-Unis]	When Randomized Clinical Trials and Real-World Evidence Say the Same: Tocilizumab and Its Cardiovascular Safety.
000014 (2020)	Puja Mehta ; Jessica J. Manson	What Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis?
000020 (2020)	Jared Radbel [États-Unis] ; Navaneeth Narayanan [États-Unis] ; Pinki J. Bhatt [États-Unis]	Use of tocilizumab for COVID-19 infection-induced cytokine release syndrome: A cautionary case report.
000023 (2020)	Yehyun Park [Corée du Sud] ; Jae Hee Cheon [Corée du Sud]	Update on the Treatment of Behcet's Disease of the Small Bowel with Biologic Agents.
000024 (2020)	Joel Hirsh ; Patrick Wood ; Angela Keniston ; Dennis Boyle ; Itziar Quinzanos ; Liron Caplan ; Lisa Davis	Universal Health Literacy Precautions Are Associated With a Significant Increase in Medication Adherence in Vulnerable Rheumatology Patients
000034 (2020)	Angelika Batta ; Bhupinder Singh Kalra ; Raj Khirasaria	Trends in FDA drug approvals over last 2 decades: An observational study
000042 (2020)	Prakhar Vijayvargiya [États-Unis] ; Zerelda Esquer Garrigos [États-Unis] ; Natalia E. Castillo Almeida [États-Unis] ; Pooja R. Gurram [États-Unis] ; Ryan W. Stevens [États-Unis] ; Raymund R. Razonable [États-Unis]	Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof)
000050 (2020)	Daichi Fukaya [Japon] ; Tsutomu Inoue [Japon] ; Yuta Kogure [Japon] ; Hiroshi Kajiyama [Japon] ; Keisuke Ishizawa [Japon] ; Takeru Seto [Japon] ; Hajime Hasegawa [Japon] ; Toshihide Mimura [Japon] ; Hirokazu Okada [Japon]	Tocilizumab-induced immunocomplex glomerulonephritis: a report of two cases.
000054 (2020)	Rongda Li [République populaire de Chine] ; Qi Wan [République populaire de Chine] ; Pan Chen [République populaire de Chine] ; Shufen Mao [République populaire de Chine] ; Qiuju Wang [République populaire de Chine] ; Xiaoxin Li [République populaire de Chine] ; Yi Yang [République populaire de Chine] ; Li Dong [République populaire de Chine]	Tocilizumab treatment in Felty's syndrome.
000055 (2020)	Pan Luo [République populaire de Chine] ; Yi Liu [République populaire de Chine] ; Lin Qiu [République populaire de Chine] ; Xiulan Liu [République populaire de Chine] ; Dong Liu [République populaire de Chine] ; Juan Li [République populaire de Chine]	Tocilizumab treatment in COVID-19: A single center experience.
000058 (2020)	Masaki Shimizu [Japon] ; Mao Mizuta [Japon] ; Nami Okamoto [Japon] ; Takahiro Yasumi [Japon] ; Naomi Iwata [Japon] ; Hiroaki Umebayashi [Japon] ; Yuka Okura [Japon] ; Noriko Kinjo [Japon] ; Tomohiro Kubota [Japon] ; Yasuo Nakagishi [Japon] ; Kenichi Nishimura [Japon] ; Mariko Mohri [Japon] ; Masato Yashiro [Japon] ; Junko Yasumura [Japon] ; Hiroyuki Wakiguchi [Japon] ; Masaaki Mori [Japon]	Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
000061 (2020)	Ver Nica Cantarín-Extremera [Espagne] ; María Jiménez-Legido [Espagne] ; Anna Duat-Rodríguez [Espagne] ; Marta García-Fernández [Espagne] ; Nelmar Valentina Ortiz-Cabrera [Espagne] ; María Luz Ruiz-Falc Rojas [Espagne] ; Luis González-Gutiérrez-Solana [Espagne]	Tocilizumab in pediatric refractory status epilepticus and acute epilepsy: Experience in two patients.
000064 (2020)	Juan Ceballos-Macías José [Oman] ; Raúl Rivera-Moscoso ; Alberto Flores-Real Jorge ; Joel Vargas-Sánchez ; Guillermo Ortega-Gutiérrez ; Ram N Madriz-Prado ; Pablo De La Cruz Velasco-Ramos ; Eloy Mu Oz-Monroy Omar ; Carolina Meneses-Pérez Anna ; Nancy Fernández-Morales Irma ; Alfredo Hernández-Moreno	Tocilizumab in glucocorticoid-resistant graves orbitopathy. A case series report of a mexican population.
000070 (2020)	Yasmine F. Ibrahim [Égypte] ; Rabab A. Moussa [Égypte] ; Asmaa M A. Bayoumi [Égypte] ; Al-Shaimaa F. Ahmed [Égypte]	Tocilizumab attenuates acute lung and kidney injuries and improves survival in a rat model of sepsis via down-regulation of NF-κB/JNK: a possible role of P-glycoprotein.
000072 (2020)	Rakesh Awasthi [États-Unis] ; Lida Pacaud [États-Unis] ; Edward Waldron [États-Unis] ; Constantine S. Tam [Australie] ; Ulrich J Ger [Autriche] ; Peter Borchmann [Allemagne] ; Samantha Jaglowski [États-Unis] ; Stephen Ronan Foley [Canada] ; Koen Van Besien [États-Unis] ; Nina D. Wagner-Johnston [États-Unis] ; Marie José Kersten [Pays-Bas] ; Stephen J. Schuster [États-Unis] ; Gilles Salles [France] ; Richard T. Maziarz [États-Unis] ; Özlem Anak [États-Unis] ; Christopher Del Corral [États-Unis] ; Jufen Chu [États-Unis] ; Irina Gershgorin [États-Unis] ; Iulian Pruteanu-Malinici [États-Unis] ; Abhijit Chakraborty [États-Unis] ; Karen Thudium Mueller [États-Unis] ; Edmund K. Waller [États-Unis]	Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/AbsEn.i -k "clinical" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/AbsEn.i  \
                -Sk "clinical" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    clinical
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021